过氧化物酶体增殖物激活受体γ(PPARg)等多因子检测试剂盒(流式荧光发光法)
Multiplex Assay Kit for Peroxisome Proliferator Activated Receptor Gamma (PPARg) ,etc. by FLIA (Flow Luminescence Immunoassay)
PPAR-G; PPARG1; PPARG2; NR1C3; Glitazone Receptor; Nuclear Receptor Subfamily 1 Group C Member 3
(注:单次混测多因子不超过8个指标 )
- 编号LMA886Hu
- 物种Homo sapiens (Human,人) 相同的名称,不同的物种。
- 实验方法双抗夹心
- 反应时长3.5h
- 检测范围0.01-10ng/mL
- 灵敏度最小可检测剂量小于等于0.003 ng/mL.
- 样本类型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
- 下载 英文说明书 中文说明书
- 规格 8指标数 7指标数 6指标数 5指标数 4指标数 3指标数 2指标数1指标数
- 价格 ¥ 2359 ¥ 2449 ¥ 2586 ¥ 2767 ¥ 2948 ¥ 3221 ¥ 3629 计算器 ¥ 4536 添加到价格计算器
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
特异性
本试剂盒用于检测过氧化物酶体增殖物激活受体γ(PPARg)等多因子检测试剂盒(流式荧光发光法),经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制,不可能完成对所有相关或相似物质交叉反应检测,因此本试剂盒有可能与未经检测的其它物质有交叉反应。
回收率
分别于定值血清及血浆样本中加入一定量的过氧化物酶体增殖物激活受体γ(PPARg)等多因子检测试剂盒(流式荧光发光法)(加标样品),重复测定并计算其均值,回收率为测定值与理论值的比率。
样本 | 回收率范围(%) | 平均回收率(%) |
serum(n=5) | 92-101 | 96 |
EDTA plasma(n=5) | 90-99 | 96 |
heparin plasma(n=5) | 97-105 | 101 |
sodium citrate plasma(n=5) | 79-103 | 95 |
精密度
精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差:取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次,分别计算不同浓度样本的平均值及SD值。
批间差:选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定,每个样本使用同一试剂盒重复测定8次,分别计算不同浓度样本的平均值及SD值。
批内差: CV<10%
批间差: CV<12%
线性
在定值血清及血浆样本内加入适量的过氧化物酶体增殖物激活受体γ(PPARg)等多因子检测试剂盒(流式荧光发光法),并倍比稀释成1:2,1:4,1:8,1:16的待测样本,线性范围即为稀释后样本中过氧化物酶体增殖物激活受体γ(PPARg)等多因子检测试剂盒(流式荧光发光法)含量的测定值与理论值的比率。
样本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 94-101% | 89-101% | 80-97% | 78-104% |
EDTA plasma(n=5) | 93-102% | 81-102% | 88-95% | 80-104% |
heparin plasma(n=5) | 89-99% | 91-102% | 87-95% | 80-88% |
sodium citrate plasma(n=5) | 80-99% | 96-105% | 94-102% | 93-105% |
稳定性
经测定,试剂盒在有效期内按推荐温度保存,其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响,实验室的环境条件需尽量保持一致,尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
实验流程
1. 实验前标准品、试剂及样本准备;
2. 加样(标准品、样本、磁珠)标准品或样本100μL及磁珠10μL,
37°C酶标板振荡器孵育90分钟;
3. 磁吸甩干,加检测溶液A100μL,37°C酶标板振荡器孵育60分钟;
4. 磁吸洗板3次;
5. 加检测溶液B100μL,37°C振动孵育30分钟;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋涡震荡2分钟后读数。
实验原理
将过氧化物酶体增殖物激活受体γ(PPARg)等多因子检测试剂盒(流式荧光发光法)抗体包被于磁珠,制成固相载体,向微孔中分别加入标准品或标本以及磁珠,其中的过氧化物酶体增殖物激活受体γ(PPARg)等多因子检测试剂盒(流式荧光发光法)与连接于固相载体上的抗体结合,然后加入生物素化的过氧化物酶体增殖物激活受体γ(PPARg)等多因子检测试剂盒(流式荧光发光法)抗体,将未结合的生物素化抗体洗净后,加入PE标记的亲和素,再次彻底洗涤后即可上机读数。MFI值和样品中的过氧化物酶体增殖物激活受体γ(PPARg)等多因子检测试剂盒(流式荧光发光法)呈正相关。
赠品
增值服务
相关产品
编号 | 适用物种:Homo sapiens (Human,人) | 应用(仅供研究使用,不用于临床诊断!) |
APA886Hu01 | 过氧化物酶体增殖物激活受体γ(PPARg)活性蛋白 | Cell culture; Activity Assays. |
RPA886Hu02 | 过氧化物酶体增殖物激活受体γ(PPARg)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA886Hu01 | 过氧化物酶体增殖物激活受体γ(PPARg)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA886Hu02 | 过氧化物酶体增殖物激活受体γ(PPARg)多克隆抗体 | WB; IHC; ICC; IP. |
PAA886Hu01 | 过氧化物酶体增殖物激活受体γ(PPARg)多克隆抗体 | WB; IHC; ICC; IP. |
LAA886Hu71 | 过氧化物酶体增殖物激活受体γ(PPARg)多克隆抗体(生物素标记) | WB; IHC; ICC. |
MAA886Hu22 | 过氧化物酶体增殖物激活受体γ(PPARg)单克隆抗体 | WB; IHC; ICC; IP. |
SEA886Hu | 过氧化物酶体增殖物激活受体γ(PPARg)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA886Hu | 过氧化物酶体增殖物激活受体γ(PPARg)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
KSA886Hu01 | 过氧化物酶体增殖物激活受体γ(PPARg)检测试剂盒DIY材料(酶联免疫吸附试验法) | Main materials for "Do It (ELISA Kit) Yourself". |
参考文献
杂志 | 参考文献 |
Neuroscience Letters | Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis [Pubmed: 24021801] |
J Cell Biochem. | Nonivamide enhances miRNA let‐7d expression and decreases adipogenesis PPARγ expression in 3T3‐L1 cells [Pubmed:25704235] |
Osteoarthritis Cartilage | Establishment of a rabbit model to study the influence of advanced glycation end products accumulation on osteoarthritis and the protective effect of pioglitazone [PubMed: 26321377] |
J Clin Diagn Res. | Evaluation of Protein Kinase Cβ and PPARγ Activity in Diabetic Rats Supplemented with Momordica charantia [pmc:PMC4866090] |
Journal of Clinical&Diagnostic Research | Evaluation of Protein Kinase Cβ and PPARγ Activity in Diabetic RatsSupplemented with Momordica charantia. [pubmed:27190792] |
Osteoarthritis and Cartilage | Establishment of a rabbit model to study the influence of advanced glycation end productsaccumulation on osteoarthritis and the protective effect of pioglitazone. [pubmed:26321377] |
Neuroscience Letters | Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis [pubmed:28483651] |
European Journal of Immunology | Engulfment of Hb‐activated platelets differentiates monocytes into pro‐inflammatory macrophages in PNH patients [Pubmed:29677388] |
Histochemistry and Cell Biology | Simpson–Golabi–Behmel syndrome human adipocytes reveal a changing phenotype throughout differentiation [Pubmed:29574488] |
molecular and cellular biochemistry | Maternal omega-3 fatty acids and vitamin E improve placental angiogenesis in late-onset but not early-onset preeclampsia [Pubmed: 31420792] |
Nutrients. | Hyperglycemia Changes Expression of Key Adipogenesis Markers (C/EBPα and PPARᵞ) and Morphology of Differentiating Human Visceral Adipocytes [Pubmed: 31398873] |
journal of biochemical and molecular toxicology | Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells [Pubmed: 31916655] |
J Cosmet Dermatol | In©\vitro effect of pine bark extract on melanin synthesis, tyrosinase activity, production of endothelin©\1 and PPAR in cultured melanocytes exposed to Ultraviolet?¡ [33960120] |
American Chemical Society | TRPA1 Agonist Cinnamaldehyde Decreases Adipogenesis in 3T3-L1 Cells More Potently than the Non-agonist Structural Analog Cinnamyl Isobutyrate [33403292] |
PLoS One | Quantitative real-time measurement of endothelin-1-induced contraction in single non-activated hepatic stellate cells [34343209] |
Prostaglandins Leukot Essent Fatty Acids | Maternal Vitamin D Deficiency Reduces Docosahexaenoic Acid, Placental Growth Factor and Peroxisome Proliferator Activated Receptor Gamma levels in the Pup … [34768025] |
Food and Chemical Toxicology | Melatonin attenuates cisplatin-induced acute kidney injury in mice: Involvement of PPARα and fatty acid oxidation [Pubmed:35367536] |